New drug NRM-823 takes on Hard-to-Treat cancers

NCT ID NCT07182149

Recruiting now Disease control Sponsor: Normunity AccelCo, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NRM-823 (a bispecific T-cell engager drug)
What this could lead to: If it works, this could point toward a new treatment option for several advanced cancers that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. It may not work, and side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus cervical cancer endometrial cancer endometrium neoplasm esophageal adenocarcinoma esophageal squamous cell carcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma ovarian cancer Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER ENDOMETRIAL CANCER ESCC ESOPHAGEAL ADENOCARCINOMA GASTRIC ADENOCARCINOMA GEJ ADENOCARCINOMA HNSCC NSCLC OVARIAN CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

Normunity Investigational Site
RECRUITING

Denver, Colorado, 80220, United States
Normunity Investigational Site
RECRUITING

New Haven, Connecticut, 06519, United States
Normunity Investigational Site
RECRUITING

Minneapolis, Minnesota, 55425, United States
Normunity Investigational Site
RECRUITING

Maumee, Ohio, 43537, United States
Normunity Investigational Site
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Normunity Investigational Site
RECRUITING

Nashville, Tennessee, 37203, United States
Normunity Investigational Site
RECRUITING

Dallas, Texas, 75230, United States
Normunity Investigational Site
RECRUITING

San Antonio, Texas, 78229, United States
Normunity Investigational Site
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.